reports
Boston Scientific Corp: 1 director
A director at Boston Scientific Corp sold 14,506 shares at 66.450USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
- Valens Research
Valens Equity Insights and Inflections - 2022 03 15
Ichor Holdings, Ltd. (ICHR) is the dominant player in a critical memory chip subindustry, and it is improving profitability coming out of a difficult two-year period for the industry. Uniform Accounting highlights that the market is missing the company's improving fundamentals, creating an opportunity for equity upside. Ichor is the biggest and highest quality fluid and gas delivery system manufacturer, a key supplier to the growing memory chip market. Difficult supply dynamics in the memory ma...
ANET ARISTA NETWORKS INC.
TMO THERMO FISHER SCIENTIFIC INC.
NVDA NVIDIA CORPORATION
LDOS LEIDOS HOLDINGS INC.
ICE INTERCONTINENTAL EXCHANGE INC.
GILD GILEAD SCIENCES INC.
CPRT COPART INC.
CME CME GROUP INC. CLASS A
TTD TRADE DESK INC. CLASS A
ICHR ICHOR HOLDINGS LTD.
- Valens Research
BSX - Embedded Expectations Analysis - 2022 03 08
Boston Scientific (BSX) currently trades near corporate but below historical averages relative to Uniform earnings, with a 25.5x Uniform P/E (Fwd. V/E'). At these levels, markets are pricing in expectations for Uniform ROA to remain stable at 27% levels, accompanied by 5% Uniform asset growth. Meanwhile, analysts expect Uniform ROA to improve to 29% in 2023, accompanied by 3% Uniform asset growth. If sustained going forward, these levels would imply a stock price closer to $44, representing a...
Moody's upgrades Boston Scientific to Baa1, outlook stable
Rating Action: Moody's upgrades Boston Scientific to Baa1, outlook stable. Global Credit Research- 23 Feb 2022. New York, February 23, 2022-- Moody's Investors Service upgraded Boston Scientific Corporation's senior unsecured rating to Baa1 from Baa2.
- Valens Research
Valens Equity Insights and Inflections - 2021 12 14
ExlService (EXLS) is using AI to become one of the highest growth, most profitable BPOs. Uniform Accounting highlights that the market is significantly mispricing the company's future growth potential, signaling the potential for equity upside. With companies looking to outsource more of their operations and adopt more technology solutions, ExlService is well positioned to grow as its clients look to outsource more of their businesses. The company uses industry specific technology to develop ...
URI UNITED RENTALS INC.
SWK STANLEY BLACK & DECKER INC.
TXN TEXAS INSTRUMENTS INCORPORATED
MO ALTRIA GROUP INC
EXLS EXLSERVICE HOLDINGS INC.
CVS CVS HEALTH CORPORATION
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
GNRC GENERAC HOLDINGS INC.
PDCE PDC ENERGY INC.
TWTR TWITTER INC.
- Valens Research
BSX - Embedded Expectations Analysis - 2021 12 07
Boston Scientific (BSX) currently trades near corporate and historical averages relative to Uniform earnings, with a 21.4x Uniform P/E (Fwd. V/E'). At these levels, markets are pricing in expectations for Uniform ROA to recover to 27%, accompanied by 5% Uniform asset growth. Meanwhile, analysts expect Uniform ROA to improve to 29% in 2022, accompanied by 6% Uniform asset growth. If sustained going forward, these levels would imply a stock price closer to $45, representing approximately 17% eq...
BOSTON SCIENTIFIC sees a downgrade to Slightly Negative on account of ...
The independent financial analyst theScreener just lowered the general evaluation of BOSTON SCIENTIFIC (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date October 19, 2021, the closing price was USD...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.